Equity Profile

RGEN

Repligen Corporation

Health CareLife Sciences Tools & Services$9.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in bioprocessing, providing products that support the development and manufacturing of biologics, which are essential for therapies and vaccines.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.46

Revenue

Revenue growth is vital for assessing the company's market demand and overall health, especially in the competitive life sciences sector.

$207M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing operational efficiencies.
Plans to invest in research and development for new bioprocessing technologies.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Repligen's upcoming earnings, expecting solid EPS and revenue figures. The company has a strong track record of beating earnings estimates.

Bull Case

If Repligen continues its trend of exceeding EPS estimates, it could signal strong operational performance and market demand, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about future growth and profitability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.46

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$207M

Revenue growth is vital for assessing the company's market demand and overall health, especially in the competitive life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of $0.46 or higher?

This figure is crucial as it will indicate the company's ability to maintain profitability and could influence investor confidence.

What revenue figure will Repligen report, and how does it compare to the $207M consensus?

Revenue performance is a key indicator of market demand and growth potential, impacting future guidance and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Repligen's ability to leverage new product developments, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Repligen has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The company's recent investments in R&D could yield new products that drive revenue growth beyond current expectations.

Key Risk

If the company reports revenue significantly above $207M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Repligen's ability to sustain its growth trajectory amid competitive pressures in the life sciences sector.

Bull Confirmed If

Achieving an EPS of $0.46 or higher with revenue exceeding $207M would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.41 or revenue below $205M would indicate potential challenges in growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 4.72% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on operational efficiencies and cost management strategies.
3Insights into market demand for bioprocessing products.
4Management's outlook on future growth and potential challenges.
5Responses to analyst questions regarding competitive pressures in the life sciences sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$0.46

Revenue

Revenue growth is vital for assessing the company's market demand and overall health, especially in the competitive life sciences sector.

$207M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding expectations by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing operational efficiencies.
Plans to invest in research and development for new bioprocessing technologies.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Repligen's upcoming earnings, expecting solid EPS and revenue figures. The company has a strong track record of beating earnings estimates.

Bull Case

If Repligen continues its trend of exceeding EPS estimates, it could signal strong operational performance and market demand, potentially leading to a stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about future growth and profitability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.46

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$207M

Revenue growth is vital for assessing the company's market demand and overall health, especially in the competitive life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Repligen achieve an EPS of $0.46 or higher?

This figure is crucial as it will indicate the company's ability to maintain profitability and could influence investor confidence.

What revenue figure will Repligen report, and how does it compare to the $207M consensus?

Revenue performance is a key indicator of market demand and growth potential, impacting future guidance and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Repligen's ability to leverage new product developments, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

Repligen has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The company's recent investments in R&D could yield new products that drive revenue growth beyond current expectations.

Key Risk

If the company reports revenue significantly above $207M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Repligen's ability to sustain its growth trajectory amid competitive pressures in the life sciences sector.

Bull Confirmed If

Achieving an EPS of $0.46 or higher with revenue exceeding $207M would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.41 or revenue below $205M would indicate potential challenges in growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a potential stock increase of around 3.95%, confirming strong operational health.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 4.72% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Any updates on operational efficiencies and cost management strategies.
3Insights into market demand for bioprocessing products.
4Management's outlook on future growth and potential challenges.
5Responses to analyst questions regarding competitive pressures in the life sciences sector.